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Treatment of Ventricular Arrhythmias
A Lesson in Not Throwing Out the Baby With the Bathwater?*Vivek Y. Reddy, MD, Marc A. Miller, MDJust because something doesn’t do what you
planned it to do doesn’t mean it’s useless.
–Thomas Edison (1)SEE PAGE 984C ardiac catheter ablation of scar-related ven-tricular tachycardia (VT) is safe and effectivefor reducing recurrent VT episodes and
implantable cardioverter-deﬁbrillator (ICD) therapies
(2). Nevertheless, even in high-volume centers with
skilled operators, between one-third and one-half of
patients will have a recurrence of sustained ventricu-
lar arrhythmias (VAs) within 1 year after catheter
ablation for scar VT (2,3). Predictors of VA recurrence
after ablation include nonischemic substrate, heart
failure class, unstable/unmappable VTs, persistent
inducibility at the end of the procedure, and presen-
tation with VT storm (4). Because failure to control
recurrent VAs is associated with a higher risk of sub-
sequent death, there has been intense interest in
the development of adjunctive therapies to further
suppress VAs in patients not adequately controlled
with pharmacological and conventional catheter abla-
tion procedures (5).
To this point, the sympathetic nervous system has
long been implicated in the initiation and perpetua-
tion of VAs (6–8). Most recently, nonrandomized
studies have suggested that either thoracic epidural
anesthesia or left/bilateral stellate gangliectomy, a
minimally invasive surgical procedure, can modulate*Editorials published in the JACC: Cardiovascular Interventions reﬂect the
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tents of this paper to disclose.the sympathetic nervous system and signiﬁcantly
reduce recurrent VAs in patients in whom conven-
tional therapies fail (9,10). Not surprisingly, inves-
tigators have turned their eye toward even “simpler”
methods for modulating the autonomic nervous
system—catheter ablation of the sympathetic nerve
ﬁbers coursing in the renal arterial adventitia (renal
sympathetic denervation [RSDN]). Although the
Symplicity HTN-3 (Renal Denervation in Patients
With Uncontrolled Hypertension) trial did not
demonstrate a beneﬁt of RSDN (compared with pla-
cebo) for the treatment of resistant essential hyper-
tension, RSDN has been shown to modify measures of
sympathetic overactivity, such as renal/whole-body
norepinephrine spillover and muscle sympathetic
nerve activity (11,12). Furthermore, pre-clinical data
have demonstrated that RSDN can suppress VAs
during acute ischemia, and case reports of patients
with either recurrent VAs after catheter ablation or
who presented with electrical storm suggests that
RSDN may be beneﬁcial (13–16). However, it should be
noted that the total published clinical experience
numbers only 6 patients from 5 institutions and did
not account for confounding variables (e.g., upgrade
to cardiac resynchronization therapy, titration of
antiarrhythmic therapies), which could have over-
estimated the perceived effect of RSDN.In this issue of the Journal, Armaganijan et al. (17)
shed additional light on the important clinical ques-
tion of whether catheter-based RSDN has the potential
to reduce recurrent VAs in patients with cardiomyop-
athy. In this single-center prospective study, the au-
thors analyzed the 6-month outcomes of 10 patients
undergoing RSDN for refractory VAs. The inclusion
criteria were VAs refractory to optimalmedical therapy
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992with either previous failed cardiac ablation (n ¼ 2) or
poor unsuitabilty for cardiac ablation due to the pres-
ence of cardiac thrombus (n ¼ 3) or presentation with
polymorphic VT or ventricular ﬁbrillation (n¼ 5). More
than one-half the patients’ VT substrate was due to
Chagas disease (n ¼ 6). The overall mean left ventric-
ular ejection fraction was 31  11%, and patients were
taking an average of 2 antiarrhythmic medications on
presentation. RSDNwas performedwith 1 of 2 different
catheters: an off-the-shelf irrigated ablation catheter
(n ¼ 7) (Therapy Cool Path, St. Jude Medical, St. Paul,
Minnesota) with which a minimum of 4 ablations per
renal artery were delivered (18), or a dedicated RSDN
catheter (n ¼ 3) (EnligHTN, St. Jude Medical) with
which a minimum of 8 ablation lesions per renal artery
were delivered. All ICDs were programmed between
120 and 130 beats/min after RSDN. The authors report
only 1 signiﬁcant procedure-related adverse event:
bradycardia requiring transient intravenous epineph-
rine to correct. There were no vascular or renal com-
plications, including the absence of either renal artery
dissection or renal artery stenosis (at 6 months of
follow-up). Three patients died before completing
6 months of follow-up: 2 died of progressive heart
failure and 1 died of sepsis. In total, 7 patients
completed the 6 months of follow-up. When
comparing the 6 months before RSDN to the 6 months
after RSDN, there was a dramatic reduction in VAs and
ICD therapies: the median number of VT/VF episodes
decreased from 28.5 (range, 1 to 106) to 0 (range, 0 to 9),
antitachycardiac pacing therapy decreased from 20.5
(range, 0 to 52) to 0 (range, 0 to 7), and the number of
ICD shocks decreased from 8 (range, 0 to 88) to
0 (range, 0 to 3). Although the majority (80%) of pa-
tients were considered RSDN responders, 2 patients
appeared to derive no discernible beneﬁt (i.e., no sig-
niﬁcant reduction in VA burden) from the procedure.
Importantly, the authors report that no patients
required an increase in antiarrhythmic therapy.
The authors have demonstrated that RSDN is
feasible and (likely) safe in patients with scar-related
VAs, without any deleterious effects on blood
pressure or renal function. Furthermore, RSDN, in
conjunction with antiarrhythmic therapy, maydramatically reduce the VA burden in patients with
mixed substrates who are not considered candidates
for catheter ablation. The strengths of this study
include prospective enrollment and data collection as
well as a prescriptive approach to deﬁbrillator pro-
gramming for the detection of VAs. However, enthu-
siasm for RSDN in the treatment of VAs has to be
weighed against the realization that: 1) although this
series represents the largest published experience to
date, it is still a small number of patients (n ¼ 10);
2) heart failure optimization, hospitalization, and
anesthesia can potentially affect VA burden and sym-
pathetic tone; 3) RSDNwas performed for patients who
were not candidates for catheter ablation, so its role as
adjunctive therapy remains unknown; 4) measures of
sympathetic tone/functionwere not performed, so one
cannot know whether sympathetic tone was actually
modiﬁed with RSDN (19). Thus, the study by Armaga-
nijan et al. is an important step toward our under-
standing of the potential role of catheter-based RSDN
for the control of scar-related VAs, but studies of RSDN
in essential hypertension have taught us not to pop the
champagne corks just yet. However, it is interesting to
speculate that patients with VAs might represent a
population that, because of their highly overactive
sympathetic state, may beneﬁt greatly from a therapy
like RSDN. As indicated on the clinical trials
registration site, this hypothesis is being tested pro-
spectively in a several such randomized clinical trials
(NCT01747837, NCT01858194, NCT02071511).
Furthermore, in addition to VAs, RSDN is also being
explored as an adjunctive treatment for atrial ﬁbrilla-
tion, another arrhythmia with autonomic overactivity
(20,21). Ultimately, well-designed prospective, ran-
domized clinical trials with appropriate patient blind-
ing are needed to determine whether the beneﬁcial
antisympathetic effects of RSDN may prove effective
in the control of cardiac arrhythmias.
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